

# TRAIN - Key note lecture

Thursday March 2<sup>nd</sup>, 4:30 pm

CRC Hannover  
Feodor-Lynen-Straße 15  
Room HO.072

Forging high-value  
collaborations between  
academia, biotech and big  
pharma - the Evotec approach

Cord Dohrmann, Ph.D.  
CSO Evotec AG



## Who is Cord Dohrmann?

Dr. Cord Dohrmann joined Evotec AG as Chief Scientific Officer and Member of the Management Board in 2010. He has spent over 20 years in biomedical research at leading academic institutions and in the biotech industry. He started his academic career studying Biology at Tübingen University and conducting research as a DAAD scholar at Duke University, Durham, USA. Dr. Dohrmann completed his MA thesis at the Max-Planck Institute in Tübingen and subsequently enrolled at the Harvard Medical School in Boston, USA, where he received his Ph.D. in Cell and Developmental Biology in 1996.

Dr. Dohrmann continued his career as a Shiseido research fellow at the Massachusetts General Hospital in Boston before joining DeveloGen in 1999. He served the company in various management positions including CEO, leading DeveloGen from a start-up to an internationally recognised metabolic disease company. Dr. Dohrmann has been advising the European Commission, the Max-Planck-Institute as well as venture capital firms and authored and co-authored a number of publications and patents.

Host: TRAIN Academy ([train@twincore.de](mailto:train@twincore.de)); Dr. Thomas Hesterkamp, DZIF